跨肺压导向机械通气策略在静脉-静脉体外膜氧合治疗的重度急性呼吸窘迫综合征中的应用
该单中心、前瞻性随机对照试验纳入104例接受静脉-静脉体外膜氧合(VV-ECMO)的重度急性呼吸窘迫综合征(ARDS)患者,随机分为跨肺压导向通气组(n=52)与肺休息策略组(n=52),肺休息组2例在建立VV-ECMO期间发生心脏骤停未接受干预,最终102例纳入分析。跨肺压导向组VV-ECMO成功撤机比例显著高于肺休息组(71.2% vs 48.0%,p=0.017)。在VV-ECMO支持期间,跨肺压导向组的驱动压、潮气量和机械功率显著更低,呼气末正压显著更高;随时间推移,跨肺压导向组白细胞介素-1β、白细胞介素-6和白细胞介素-8水平显著更低,白细胞介素-10显著更高;VV-ECMO支持后跨肺压导向组肺密度显著更低。结论认为跨肺压导向通气策略可提高重度ARDS患者VV-ECMO成功撤机比例。
要点
- 在重度ARDS接受VV-ECMO的患者中,跨肺压导向通气组VV-ECMO成功撤机比例为71.2%,肺休息组为48.0%,差异有统计学意义(p=0.017)。
- VV-ECMO支持期间,跨肺压导向组较肺休息组的驱动压、潮气量和机械功率显著更低,呼气末正压显著更高。
- 随时间推移,跨肺压导向组较肺休息组的白细胞介素-1β、白细胞介素-6和白细胞介素-8水平显著更低,白细胞介素-10显著更高。
- VV-ECMO支持后,跨肺压导向组肺密度显著低于肺休息组。
- 该研究为单中心、前瞻性随机对照试验,最终纳入102例患者进行分析。
适用人群与场景
- 接受静脉-静脉体外膜氧合(VV-ECMO)的重度急性呼吸窘迫综合征(ARDS)患者。
处置流程与药物剂量
- 跨肺压导向通气策略:根据跨肺压测量调整呼吸机参数,在VV-ECMO支持期间驱动压、潮气量和机械功率显著更低,呼气末正压显著更高。
- 肺休息策略:作为对照通气策略。
研究设计与关键结果
- 研究类型:单中心、前瞻性、随机对照试验;设置:16张床位的呼吸ICU,三级学术医疗中心;样本量:104例随机(跨肺压导向组n=52,肺休息组n=52),肺休息组2例在建立VV-ECMO期间发生心脏骤停未接受指定干预,最终102例纳入分析。
- 主要终点:跨肺压导向组VV-ECMO成功撤机比例显著高于肺休息组(71.2% vs 48.0%,p=0.017)。
- 关键次要终点:VV-ECMO支持期间,跨肺压导向组较肺休息组驱动压、潮气量和机械功率显著更低,呼气末正压显著更高;随时间推移,跨肺压导向组白细胞介素-1β、白细胞介素-6和白细胞介素-8水平显著更低,白细胞介素-10显著更高;VV-ECMO支持后跨肺压导向组肺密度显著更低。
- 不良事件:肺休息组2例在建立VV-ECMO期间发生心脏骤停。
证据类型、等级与局限
- 证据类型:单中心、前瞻性、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受VV-ECMO的重度ARDS患者,跨肺压导向通气策略较肺休息策略可提高VV-ECMO成功撤机比例(71.2% vs 48.0%,p=0.017),并降低驱动压、潮气量和机械功率,升高呼气末正压。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Previous studies have suggested that adjusting ventilator settings based on transpulmonary pressure measurements may minimize ventilator-induced lung injury, but this has never been investigated in patients with severe acute respiratory distress syndrome supported with venovenous extracorporeal membrane oxygenation. We aimed to evaluate whether a transpulmonary pressure-guided ventilation strategy would increase the proportion of patients successfully weaned from venovenous extracorporeal membrane oxygenation support in patients with severe acute respiratory distress syndrome.
DESIGN: Single-center, prospective, randomized controlled trial.
SETTING: Sixteen-bed, respiratory ICU at a tertiary academic medical center.
PATIENTS: Severe acute respiratory distress syndrome patients receiving venovenous extracorporeal membrane oxygenation.
INTERVENTIONS: One-hundred four patients were randomized to transpulmonary pressure-guided ventilation group (n = 52) or lung rest strategy group (n = 52) groups. Two patients had cardiac arrest during establishment of venovenous extracorporeal membrane oxygenation in the lung rest group did not receive the assigned intervention. Thus, 102 patients were included in the analysis.
MEASUREMENTS AND MAIN RESULTS: The proportion of patients successfully weaned from venovenous extracorporeal membrane oxygenation in the transpulmonary pressure-guided group was significantly higher than that in the lung rest group (71.2% vs 48.0%; p = 0.017). Compared with the lung rest group, driving pressure, tidal volumes, and mechanical power were significantly lower, and positive end-expiratory pressure was significantly higher, in the transpulmonary pressure-guided group during venovenous extracorporeal membrane oxygenation support. In the transpulmonary pressure-guided group, levels of interleukin-1β, interleukin-6, and interleukin-8 were significantly lower, and interleukin-10 was significantly higher, than those of the lung rest group over time. Lung density was significantly lower in the transpulmonary pressure-guided group after venovenous extracorporeal membrane oxygenation support than in the lung rest group.
CONCLUSIONS: A transpulmonary pressure-guided ventilation strategy could increase the proportion of patients with severe acute respiratory distress syndrome successfully weaned from venovenous extracorporeal membrane oxygenation.
参考来源
- Wang R, Sun B, Li X, et al. Mechanical Ventilation Strategy Guided by Transpulmonary Pressure in Severe Acute Respiratory Distress Syndrome Treated With Venovenous Extracorporeal Membrane Oxygenation. Crit Care Med. 2020. PMID: 32590385. doi:10.1097/CCM.0000000000004445
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。